Industry Research Reports
Home > Reports > Service & Software > Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Service & Software
Published Date: 2025-12-12
Pages: 159 Pages
Report ld: 4901243
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Gene Cell Therapy CDMO Market Size(US$)
CAGR 2025-2031
7.8%
Market Size,2031
USD 3,925
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 2,500 million
Market Forecast in 2031(Value)
US$ 3,925 million
CAGR
7.8%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2320 million in 2024 to US$ 3925 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications.
Gene Cell Therapy CDMO provides end-to-end customized R&D and manufacturing services for advanced therapies such as gene therapy and cell therapy, from process development to production scale-up. Their core strength lies in addressing the extreme complexity of using live cells or viral vectors as "drugs," encompassing vector design and construction, cell collection and modification, process development and optimization, rigorous quality control and release testing, and clinical- and commercial-grade aseptic manufacturing. This field has extremely high barriers to entry, requiring companies to possess cutting-edge biological technologies, GMP-compliant closed-loop automated production systems, and the expertise to meet stringent global regulations. They are indispensable industrialization partners for pharmaceutical companies to bring cutting-edge therapies from the laboratory to market.
Gene Cell Therapy CDMO has a highly complex cost structure, primarily including cutting-edge R&D and highly skilled human resources costs, customized GMP facilities and expensive one-time production consumables, as well as stringent quality control and testing fees. Their gross profit margins range widely (typically 30%-60% or higher), depending mainly on the uniqueness of the technology platform, process efficiency, and capacity utilization. Early highly personalized therapies face significant cost pressures due to limited scale, while mature, large-scale platform-based manufacturing (such as allogeneic therapies and viral vectors) can achieve higher profitability through standardization and capacity expansion.
The global landscape of Gene Cell Therapy CDMO is characterized by "technology leadership, regional concentration, and multi-point breakthroughs." North America remains the absolute innovation center and largest source of demand globally, boasting the most mature capital markets, top biotech companies, and leading CDMO firms, dominating technology and standard development. Europe follows closely behind, possessing strong capabilities in specific technological routes and clinical translation thanks to its deep research foundation and rigorous regulatory system. The Asia-Pacific region, especially China, is becoming the fastest-growing market globally, driven by strong policy support, the rise of domestic innovative pharmaceutical companies, and huge clinical demand. It is rapidly moving from early technology imports to independent innovation and internationalization, with South Korea and Japan also actively expanding their presence. Currently, supply chain stability, geopolitical factors, and the need for proximity to clinical centers are driving the global production capacity layout towards regionalization and diversification.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Gene Cell Therapy CDMO market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Catalent
- Lonza
- Charles River
- Oxford Biomedica
- Novartis
- OBiO
- GenScript
- Pharmaron
- Porton
- Resilience
- SK Pharmteco
- Forge Biologics
- Andelyn Biosciences
- Roslin CT
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Immune Cells
- Stem Cell
- Viral Vector
- Plasmid DNA
Segment by Application
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Hospital
- Others
Segment by Category
- Early-stage CDMO and preclinical CDMO
- Clinical-stage CDMO
- Commercial-stage CDMO
Segment by Division
- Centralized Factory Model
- Distributed Regional Production Model
CHAPTER OUTLINE
Chapter 1: Defines the Gene Cell Therapy CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; top-tier players 2024 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Gene Cell Therapy CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Gene Cell Therapy CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immune Cells
1.2.3 Stem Cell
1.2.4 Viral Vector
1.2.5 Plasmid DNA
1.3 Market Segmentation by Application
1.3.1 Global Gene Cell Therapy CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Gene Cell Therapy CDMO Revenue Estimates and Forecasts 2020-2031
2.2 Global Gene Cell Therapy CDMO Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Gene Cell Therapy CDMO Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Gene Cell Therapy CDMO Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Immune Cells Market Size by Players
3.3.2 Stem Cell Market Size by Players
3.3.3 Viral Vector Market Size by Players
3.3.4 Plasmid DNA Market Size by Players
3.4 Global Gene Cell Therapy CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Gene Cell Therapy CDMO Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Gene Cell Therapy CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Gene Cell Therapy CDMO Market Size by Type (2020-2031)
6.4 North America Gene Cell Therapy CDMO Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Gene Cell Therapy CDMO Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Gene Cell Therapy CDMO Market Size by Type (2020-2031)
7.4 Europe Gene Cell Therapy CDMO Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Gene Cell Therapy CDMO Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Gene Cell Therapy CDMO Market Size by Type (2020-2031)
8.4 Asia-Pacific Gene Cell Therapy CDMO Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Gene Cell Therapy CDMO Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Gene Cell Therapy CDMO Market Size by Type (2020-2031)
9.4 Central and South America Gene Cell Therapy CDMO Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Gene Cell Therapy CDMO Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Gene Cell Therapy CDMO Market Size by Type (2020-2031)
10.4 Middle East and Africa Gene Cell Therapy CDMO Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Gene Cell Therapy CDMO Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Catalent
11.1.1 Catalent Corporation Information
11.1.2 Catalent Business Overview
11.1.3 Catalent Gene Cell Therapy CDMO Product Features and Attributes
11.1.4 Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.1.5 Catalent Gene Cell Therapy CDMO Revenue by Product in 2024
11.1.6 Catalent Gene Cell Therapy CDMO Revenue by Application in 2024
11.1.7 Catalent Gene Cell Therapy CDMO Revenue by Geographic Area in 2024
11.1.8 Catalent Gene Cell Therapy CDMO SWOT Analysis
11.1.9 Catalent Recent Developments
11.2 Lonza
11.2.1 Lonza Corporation Information
11.2.2 Lonza Business Overview
11.2.3 Lonza Gene Cell Therapy CDMO Product Features and Attributes
11.2.4 Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.2.5 Lonza Gene Cell Therapy CDMO Revenue by Product in 2024
11.2.6 Lonza Gene Cell Therapy CDMO Revenue by Application in 2024
11.2.7 Lonza Gene Cell Therapy CDMO Revenue by Geographic Area in 2024
11.2.8 Lonza Gene Cell Therapy CDMO SWOT Analysis
11.2.9 Lonza Recent Developments
11.3 Charles River
11.3.1 Charles River Corporation Information
11.3.2 Charles River Business Overview
11.3.3 Charles River Gene Cell Therapy CDMO Product Features and Attributes
11.3.4 Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.3.5 Charles River Gene Cell Therapy CDMO Revenue by Product in 2024
11.3.6 Charles River Gene Cell Therapy CDMO Revenue by Application in 2024
11.3.7 Charles River Gene Cell Therapy CDMO Revenue by Geographic Area in 2024
11.3.8 Charles River Gene Cell Therapy CDMO SWOT Analysis
11.3.9 Charles River Recent Developments
11.4 Oxford Biomedica
11.4.1 Oxford Biomedica Corporation Information
11.4.2 Oxford Biomedica Business Overview
11.4.3 Oxford Biomedica Gene Cell Therapy CDMO Product Features and Attributes
11.4.4 Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.4.5 Oxford Biomedica Gene Cell Therapy CDMO Revenue by Product in 2024
11.4.6 Oxford Biomedica Gene Cell Therapy CDMO Revenue by Application in 2024
11.4.7 Oxford Biomedica Gene Cell Therapy CDMO Revenue by Geographic Area in 2024
11.4.8 Oxford Biomedica Gene Cell Therapy CDMO SWOT Analysis
11.4.9 Oxford Biomedica Recent Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Business Overview
11.5.3 Novartis Gene Cell Therapy CDMO Product Features and Attributes
11.5.4 Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.5.5 Novartis Gene Cell Therapy CDMO Revenue by Product in 2024
11.5.6 Novartis Gene Cell Therapy CDMO Revenue by Application in 2024
11.5.7 Novartis Gene Cell Therapy CDMO Revenue by Geographic Area in 2024
11.5.8 Novartis Gene Cell Therapy CDMO SWOT Analysis
11.5.9 Novartis Recent Developments
11.6 OBiO
11.6.1 OBiO Corporation Information
11.6.2 OBiO Business Overview
11.6.3 OBiO Gene Cell Therapy CDMO Product Features and Attributes
11.6.4 OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.6.5 OBiO Recent Developments
11.7 GenScript
11.7.1 GenScript Corporation Information
11.7.2 GenScript Business Overview
11.7.3 GenScript Gene Cell Therapy CDMO Product Features and Attributes
11.7.4 GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.7.5 GenScript Recent Developments
11.8 Pharmaron
11.8.1 Pharmaron Corporation Information
11.8.2 Pharmaron Business Overview
11.8.3 Pharmaron Gene Cell Therapy CDMO Product Features and Attributes
11.8.4 Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.8.5 Pharmaron Recent Developments
11.9 Porton
11.9.1 Porton Corporation Information
11.9.2 Porton Business Overview
11.9.3 Porton Gene Cell Therapy CDMO Product Features and Attributes
11.9.4 Porton Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.9.5 Porton Recent Developments
11.10 Resilience
11.10.1 Resilience Corporation Information
11.10.2 Resilience Business Overview
11.10.3 Resilience Gene Cell Therapy CDMO Product Features and Attributes
11.10.4 Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 SK Pharmteco
11.11.1 SK Pharmteco Corporation Information
11.11.2 SK Pharmteco Business Overview
11.11.3 SK Pharmteco Gene Cell Therapy CDMO Product Features and Attributes
11.11.4 SK Pharmteco Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.11.5 SK Pharmteco Recent Developments
11.12 Forge Biologics
11.12.1 Forge Biologics Corporation Information
11.12.2 Forge Biologics Business Overview
11.12.3 Forge Biologics Gene Cell Therapy CDMO Product Features and Attributes
11.12.4 Forge Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.12.5 Forge Biologics Recent Developments
11.13 Andelyn Biosciences
11.13.1 Andelyn Biosciences Corporation Information
11.13.2 Andelyn Biosciences Business Overview
11.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Product Features and Attributes
11.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.13.5 Andelyn Biosciences Recent Developments
11.14 Roslin CT
11.14.1 Roslin CT Corporation Information
11.14.2 Roslin CT Business Overview
11.14.3 Roslin CT Gene Cell Therapy CDMO Product Features and Attributes
11.14.4 Roslin CT Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.14.5 Roslin CT Recent Developments
11.15 eXmoor Pharma
11.15.1 eXmoor Pharma Corporation Information
11.15.2 eXmoor Pharma Business Overview
11.15.3 eXmoor Pharma Gene Cell Therapy CDMO Product Features and Attributes
11.15.4 eXmoor Pharma Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.15.5 eXmoor Pharma Recent Developments
11.16 Advanced Therapies
11.16.1 Advanced Therapies Corporation Information
11.16.2 Advanced Therapies Business Overview
11.16.3 Advanced Therapies Gene Cell Therapy CDMO Product Features and Attributes
11.16.4 Advanced Therapies Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.16.5 Advanced Therapies Recent Developments
11.17 Catalent Biologics
11.17.1 Catalent Biologics Corporation Information
11.17.2 Catalent Biologics Business Overview
11.17.3 Catalent Biologics Gene Cell Therapy CDMO Product Features and Attributes
11.17.4 Catalent Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.17.5 Catalent Biologics Recent Developments
11.18 Patheon Pharma Services
11.18.1 Patheon Pharma Services Corporation Information
11.18.2 Patheon Pharma Services Business Overview
11.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Product Features and Attributes
11.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Revenue and Gross Margin (2020-2025)
11.18.5 Patheon Pharma Services Recent Developments
12 Gene Cell Therapy CDMOIndustry Chain Analysis
12.1 Gene Cell Therapy CDMO Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Gene Cell Therapy CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Gene Cell Therapy CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Gene Cell Therapy CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Gene Cell Therapy CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Gene Cell Therapy CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Gene Cell Therapy CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Gene Cell Therapy CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Cell Therapy CDMO as of 2024)
Table 11. Global Gene Cell Therapy CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Gene Cell Therapy CDMO Companies Headquarters
Table 13. Global Gene Cell Therapy CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Gene Cell Therapy CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Gene Cell Therapy CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Gene Cell Therapy CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Gene Cell Therapy CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Gene Cell Therapy CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 25. North America Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 27. Europe Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Gene Cell Therapy CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Gene Cell Therapy CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Gene Cell Therapy CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Gene Cell Therapy CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Catalent Corporation Information
Table 35. Catalent Description and Major Businesses
Table 36. Catalent Product Features and Attributes
Table 37. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Catalent Revenue Proportion by Product in 2024
Table 39. Catalent Revenue Proportion by Application in 2024
Table 40. Catalent Revenue Proportion by Geographic Area in 2024
Table 41. Catalent Gene Cell Therapy CDMO SWOT Analysis
Table 42. Catalent Recent Developments
Table 43. Lonza Corporation Information
Table 44. Lonza Description and Major Businesses
Table 45. Lonza Product Features and Attributes
Table 46. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Lonza Revenue Proportion by Product in 2024
Table 48. Lonza Revenue Proportion by Application in 2024
Table 49. Lonza Revenue Proportion by Geographic Area in 2024
Table 50. Lonza Gene Cell Therapy CDMO SWOT Analysis
Table 51. Lonza Recent Developments
Table 52. Charles River Corporation Information
Table 53. Charles River Description and Major Businesses
Table 54. Charles River Product Features and Attributes
Table 55. Charles River Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Charles River Revenue Proportion by Product in 2024
Table 57. Charles River Revenue Proportion by Application in 2024
Table 58. Charles River Revenue Proportion by Geographic Area in 2024
Table 59. Charles River Gene Cell Therapy CDMO SWOT Analysis
Table 60. Charles River Recent Developments
Table 61. Oxford Biomedica Corporation Information
Table 62. Oxford Biomedica Description and Major Businesses
Table 63. Oxford Biomedica Product Features and Attributes
Table 64. Oxford Biomedica Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Oxford Biomedica Revenue Proportion by Product in 2024
Table 66. Oxford Biomedica Revenue Proportion by Application in 2024
Table 67. Oxford Biomedica Revenue Proportion by Geographic Area in 2024
Table 68. Oxford Biomedica Gene Cell Therapy CDMO SWOT Analysis
Table 69. Oxford Biomedica Recent Developments
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Major Businesses
Table 72. Novartis Product Features and Attributes
Table 73. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Novartis Revenue Proportion by Product in 2024
Table 75. Novartis Revenue Proportion by Application in 2024
Table 76. Novartis Revenue Proportion by Geographic Area in 2024
Table 77. Novartis Gene Cell Therapy CDMO SWOT Analysis
Table 78. Novartis Recent Developments
Table 79. OBiO Corporation Information
Table 80. OBiO Description and Major Businesses
Table 81. OBiO Product Features and Attributes
Table 82. OBiO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. OBiO Recent Developments
Table 84. GenScript Corporation Information
Table 85. GenScript Description and Major Businesses
Table 86. GenScript Product Features and Attributes
Table 87. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. GenScript Recent Developments
Table 89. Pharmaron Corporation Information
Table 90. Pharmaron Description and Major Businesses
Table 91. Pharmaron Product Features and Attributes
Table 92. Pharmaron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Pharmaron Recent Developments
Table 94. Porton Corporation Information
Table 95. Porton Description and Major Businesses
Table 96. Porton Product Features and Attributes
Table 97. Porton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Porton Recent Developments
Table 99. Resilience Corporation Information
Table 100. Resilience Description and Major Businesses
Table 101. Resilience Product Features and Attributes
Table 102. Resilience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Resilience Recent Developments
Table 104. SK Pharmteco Corporation Information
Table 105. SK Pharmteco Description and Major Businesses
Table 106. SK Pharmteco Product Features and Attributes
Table 107. SK Pharmteco Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. SK Pharmteco Recent Developments
Table 109. Forge Biologics Corporation Information
Table 110. Forge Biologics Description and Major Businesses
Table 111. Forge Biologics Product Features and Attributes
Table 112. Forge Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Forge Biologics Recent Developments
Table 114. Andelyn Biosciences Corporation Information
Table 115. Andelyn Biosciences Description and Major Businesses
Table 116. Andelyn Biosciences Product Features and Attributes
Table 117. Andelyn Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Andelyn Biosciences Recent Developments
Table 119. Roslin CT Corporation Information
Table 120. Roslin CT Description and Major Businesses
Table 121. Roslin CT Product Features and Attributes
Table 122. Roslin CT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Roslin CT Recent Developments
Table 124. eXmoor Pharma Corporation Information
Table 125. eXmoor Pharma Description and Major Businesses
Table 126. eXmoor Pharma Product Features and Attributes
Table 127. eXmoor Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. eXmoor Pharma Recent Developments
Table 129. Advanced Therapies Corporation Information
Table 130. Advanced Therapies Description and Major Businesses
Table 131. Advanced Therapies Product Features and Attributes
Table 132. Advanced Therapies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Advanced Therapies Recent Developments
Table 134. Catalent Biologics Corporation Information
Table 135. Catalent Biologics Description and Major Businesses
Table 136. Catalent Biologics Product Features and Attributes
Table 137. Catalent Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Catalent Biologics Recent Developments
Table 139. Patheon Pharma Services Corporation Information
Table 140. Patheon Pharma Services Description and Major Businesses
Table 141. Patheon Pharma Services Product Features and Attributes
Table 142. Patheon Pharma Services Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Patheon Pharma Services Recent Developments
Table 144. Raw Materials Key Suppliers
Table 145. Distributors List
Table 146. Market Trends and Market Evolution
Table 147. Market Drivers and Opportunities
Table 148. Market Challenges, Risks, and Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Cell Therapy CDMO Product Picture
Figure 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Immune Cells Product Picture
Figure 4. Stem Cell Product Picture
Figure 5. Viral Vector Product Picture
Figure 6. Plasmid DNA Product Picture
Figure 7. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Pharmaceutical and Biotechnology Companies
Figure 9. Research and Academic Institutions
Figure 10. Hospital
Figure 11. Others
Figure 12. Gene Cell Therapy CDMO Report Years Considered
Figure 13. Global Gene Cell Therapy CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 15. Global Gene Cell Therapy CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Gene Cell Therapy CDMO Revenue Market Share by Region (2020-2031)
Figure 17. Global Gene Cell Therapy CDMO Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Immune Cells Revenue Market Share by Player in 2024
Figure 20. Stem Cell Revenue Market Share by Player in 2024
Figure 21. Viral Vector Revenue Market Share by Player in 2024
Figure 22. Plasmid DNA Revenue Market Share by Player in 2024
Figure 23. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2020-2031)
Figure 24. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2020-2031)
Figure 25. North America Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 27. North America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 34. Europe Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 37. France Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. India Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Gene Cell Therapy CDMO Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 57. Central and South America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Gene Cell Therapy CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Gene Cell Therapy CDMO Revenue (US$ Million) in 2024
Figure 63. South America Gene Cell Therapy CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Gene Cell Therapy CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Gene Cell Therapy CDMO Revenue (2020-2025) & (US$ Million)
Figure 69. Gene Cell Therapy CDMO Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Gene Cell Therapy CDMO in 2031?
The global market size of Gene Cell Therapy CDMO in 2031 was 3925 Million USD.
What is the annual compound growth rate of the global Gene Cell Therapy CDMO market size from 2025 to 2031?
Which region is expected to have the highest market share?
What was the global market size of Gene Cell Therapy CDMO in 2025?
Which companies rank high in the global Gene Cell Therapy CDMO market?
Related Reports
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2500 million in 2025 to US$ 4201 million by 2032, at a CAGR of 7.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-31
Pages: 149
USD 4900.00
(Single User License)
Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Gene Cell Therapy CDMO market size was US$ 2500 million in 2025 and is forecast to reach a readjusted size of US$ 4201 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-03-31
Pages: 108
USD 4250.00
(Single User License)
Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2500 million in 2025 and is projected to reach US$ 4201 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-19
Pages: 126
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2026
The global Gene Cell Therapy CDMO market was valued at US$ 2500 million in 2025 and is anticipated to reach US$ 4201 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-15
Pages: 128
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-12-12
Pages: 123
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gene Cell Therapy CDMO market size was US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-12-12
Pages: 105
USD 4250.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2025
The global market for Gene Cell Therapy CDMO was valued at US$ 2320 million in the year 2024 and is projected to reach a revised size of US$ 3925 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-12-12
Pages: 121
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-11
Pages: 112
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Research Report 2024
The global Gene Cell Therapy CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Published Date: 2024-04-28
Pages: 89
USD 2900.00
(Single User License)
Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
Published Date: 2024-04-28
Pages: 109
USD 3950.00
(Single User License)
Global Gene Cell Therapy CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Gene Cell Therapy CDMO market is projected to grow from US$ 2500 million in 2025 to US$ 4201 million by 2032, at a CAGR of 7.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-31
Pages: 149
USD 4900.00 (Single User License)Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Gene Cell Therapy CDMO market size was US$ 2500 million in 2025 and is forecast to reach a readjusted size of US$ 4201 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-03-31
Pages: 108
USD 4250.00 (Single User License)Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2500 million in 2025 and is projected to reach US$ 4201 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-19
Pages: 126
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2026
The global Gene Cell Therapy CDMO market was valued at US$ 2500 million in 2025 and is anticipated to reach US$ 4201 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-15
Pages: 128
USD 2900.00 (Single User License)Gene Cell Therapy CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-12-12
Pages: 123
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Gene Cell Therapy CDMO market size was US$ 2320 million in 2024 and is forecast to a readjusted size of US$ 3925 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-12-12
Pages: 105
USD 4250.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2025
The global market for Gene Cell Therapy CDMO was valued at US$ 2320 million in the year 2024 and is projected to reach a revised size of US$ 3925 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-12-12
Pages: 121
USD 2900.00 (Single User License)Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-11
Pages: 112
USD 3950.00 (Single User License)Global Gene Cell Therapy CDMO Market Research Report 2024
The global Gene Cell Therapy CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
Published: 2024-04-28
Pages: 89
USD 2900.00 (Single User License)Gene Cell Therapy CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Gene Cell Therapy CDMO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.
Published: 2024-04-28
Pages: 109
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now